FIELD OF THE INVENTION
[0001] The present invention relates to a production of a model to investigate the role
of endocannabinoid receptors in microglia in neuroinflammatory processes, neurodegenerative
diseases, or other neurological disorders.
BACKGROUND OF THE INVENTION
[0002] Microglia cells are a specialized population of macrophages that function as cell
of the innate immune system in the central nervous system (CNS). These cells comprise
10-15% of all cells in the human brain and play an important role in CNS development
as well as in maintaining proper neuronal function throughout the entire life of an
individual. Microglia cells, through their interaction with neurons, other cells,
and molecules, perform dynamic, constant monitoring of their surrounding microenvironment.
This enables microglia to detect and respond to various infections, tissue damage,
or homeostatic perturbations. However, the main function of microglial cells include
phagocytosis and the provision of trophic support as well as the continuous active
regulation of synapse formation, elimination, and plasticity in the brain (Cser6p
et al., 2020; Lee
et al., 2021). Microglia can take on a range of pro- or anti-inflammatory phenotypes to maintain
homeostasis. Neuroinflammation is characterised by persistent pro-inflammatory activation
of microglia, which releases toxic cytokines that cause widespread damage to the brain
(Young and Denovan-Wright, 2021). In this context, microglia cells can not only provide
tissue repair but can also contribute to neuronal damage by releasing harmful substances,
including inflammatory cytokines. The endocannabinoid system modulates the release
of inflammatory factors such as cytokines and could represent a functional link between
microglia and neuroinflammatory processes (De Meij, 2021). The CB1 receptor, one of
two cannabinoid receptors, is abundantly expressed in the central and peripheral nervous
system. Its expression is especially high in brain regions associated with the regulation
of emotion, mood, cognition and stress responses, suggesting a prominent role of CB1
signalling in modulating these processes. Downregulation of its expression either
pharmacological blockade or genetic disruption is associated with increased anxiety-,
and depressive-like behaviour, impaired extinction of aversive memories and increased
stress sensitivity and following onset of neuroinflammation.
[0003] Various approaches are used in order to use microglia cells as model cell lines.
For example,
US6780641B2 describes the use of amphotropic replication-incompetent retroviral vector encoding
v-myc oncogene transcribed from mouse leukemia virus LTR plus neomycin-resistant gene transcribed
from an internal SV40 early promote to generate immortalized human microglia cell
lines.
WO2021026294A1 disclosure features CX3CR1 hemizygous and/or homozygous defective cells and methods
of using such cells for the treatment of a metabolic or neurological disorder. This
approach focuses on inserting the exogenous nucleic acid molecule into the genome
of the cell at the CX3CR1 gene locus to target metabolic or neurological diseases.
The reconstitution of microglial cells after transplantation of CX3CR1
+/Grp hematopoietic cells.
[0004] In view of the above, a need for controlled microglia cell cultures that could be
used as cell models for researchers studying these cells in various contexts, such
as neuroinflammation, neurodegenerative diseases, and brain development remains.
SUMMARY OF THE INVENTION
[0005] The present invention relates to a method for immortalization of mouse brain isolated
microglia with subsequent knockout of endocannabinoid receptors to provide a reliable
model for developing strategies to treat neurodegenerative diseases. Advantageously,
the present invention provides a method that generates long-term microglial cells.
[0006] The present invention provides a novel method for obtaining immortalized microglial
endocannabinoid receptor gene knockout cells. The method comprises the following steps:
a) obtaining primary microglial cells; b) immortalization of microglial cells; c)
producing endocannabinoid receptor gene knockout in the cells. The present disclosure
further provides immortalized microglial endocannabinoid receptor gene knockout cells
obtained by the method.
BRIEF DESCRIPTION OF FIGURES
[0007] The drawings are provided as a reference to possible embodiments and are not intended
to limit the scope of the invention. Neither of the drawings nor the graphs presented
herein should be construed as limiting the scope of the invention, but merely as an
example of a possible embodiment.
Fig. 1 shows the analysis of the homogeneity of primary microglial cell culture: immunocytochemistry
was performed with anti-lba1 (a microglia-specific calcium-binding protein) antibodies.
(A) shows Iba1-positive microglia cell culture; (B) shows a quantitative analysis
of Iba1-positive microglia compared to total cell number. Data are expressed as a
mean ± standard deviation. The dots represent the number of Iba1-expressing cells.
Abbreviations: DAPI - nuclear dye; Iba1 is a microglia-specific marker.
Fig. 2 shows a comparison of the expression of β-galactosidase, an enzyme related
to cell ageing, in primary microglial cells and the BV-2 cell line (shown as dark
grey cells): the primary cells are about 16 times more prone to undergo cell senescence
(quantitative analysis) 7 days after isolation.
Fig. 3 shows microglia cells 7, 4 and 17 days after transduction with lentiviruses
containing pCW57.1-SV40 plasmid - cells rapidly proliferate and tend to reach confluence.
(A) 4X magnification; (B) 10X magnification.
Fig. 4 shows Western blot analysis of CB1 expression in Cnr1 knockout microglia. Tubulin expression serves as a control for expression. K denotes
the control protein for CB1 and tubulin, respectively.
Fig. 5 shows the phagocytic activity of microglia cells. The arrows indicate that
the cells are more inclined to engulf latex beads after stimulation with LPS.
DETAILED DESCRIPTION OF THE INVENTION
[0008] The present disclosure provides a method for generation of immortalized microglial
endocannabinoid receptor gene knockout cells, as well as immortalized microglial endocannabinoid
receptor gene knockout cells obtained by said method.
[0009] According to the present disclosure, a method for generation of immortalized microglial
endocannabinoid receptor gene knockout cells comprising the steps: a) obtaining primary
microglial cells, b) immortalizing the microglial cells, and c) producing endocannabinoid
receptor gene knockout in the cells is provided.
[0010] In some embodiments, the microglial cells that are generated by the presently disclosed
method are mammalian microglial cells. In some embodiments, the microglial cells are
rodent microglial cells. In preferred embodiments, the microglial cells are mouse
microglial cells.
[0011] In some aspects, in the presently disclosed method for generation of immortalized
microglial endocannabinoid receptor gene knockout cells, the primary microglial cells
are immortalized through viral-mediated induction of the large T-antigen. In preferred
embodiments, the viral-mediated induction of the large T-antigen is made by using
SV40 large T antigen.
[0012] In some aspects, in the presently disclosed method for generation of immortalized
microglial endocannabinoid receptor gene knockout cells, the endocannabinoid receptor
gene knockout is produced using CRISPR-Cas system. In some embodiments, the CRISPR-Cas
system is CRISPR-Cas9 nickase system.
[0013] In some embodiments, the endocannabinoid receptor gene that is knocked out in the
immortalized microglial cells according to the present invention, is
Cnr1. In other embodiments, the endocannabinoid receptor gene that is knocked out in the
immortalized microglial cells according to the present invention, is
Cnr2.
[0014] The present disclosure further provides an immortalized microglial endocannabinoid
receptor gene knockout cell. Preferably, the immortalized microglial endocannabinoid
receptor gene knockout cell is obtained by the method according to the present disclosure.
In some embodiments, the immortalized microglial endocannabinoid receptor gene knockout
cell is obtained from mouse primary microglial cell. In some embodiments, the immortalized
microglial endocannabinoid receptor gene knockout cell is an immortalized microglial
Cnr1 knockout cell. In other embodiments, the immortalized microglial endocannabinoid
receptor gene knockout cell is an immortalized microglial
Cnr2 knockout cell.
[0015] The method of the present invention advantageously combines the steps of a) obtaining
primary microglial cells, b) immortalizing the microglial cells, and c) producing
endocannabinoid receptor gene knockout in the cells.
[0016] Various methods may be suitable for obtaining primary microglial cells for use in
the method for generation of immortalized microglial endocannabinoid receptor gene
knockout cells of the present disclosure.
[0017] As used herein, the term "cell immortalization" refers to the increase in proliferative
potential of cells beyond the Hayflick limit and does not necessarily imply neoplastic
transformation. Immortalized cells differ from cultured primary cells in that they
have a genetic modification that renders them immortal. There are various methods
of rendering mammalian cells immortal under culture conditions, such as the use of
viral genes, such as the Simian Virus 40 (SV40) T antigen, overexpression of hTERT,
co-expression of the catalytic subunit of hTERT with either p53 or RB siRNA, overexpression
of Ras or Myc T58A, etc.
[0018] As used herein, the term "gene knockout" refers to a mutation of the DNA that permanently
stops the expression of the gene. This is possible in all types of cells and organisms
using specific genetic approaches. Currently, besides Cre-LoxP, conventional homologous
recombination, the fastest and most direct approach to achieve a specific gene knockout
is the use of CRISPR genome editing tools.
[0019] As used herein, the term "microglia" refers to the resident immune cells of the brain
that constantly monitor the cerebral microenvironment to respond to pathogens and
damage. Microglia are highly ramified cells and their processes are very active and
dynamic even under non-pathological conditions.
EXAMPLES
Microglia cell isolation from mice brain
[0020] Animal care and experiments were performed in accordance with the requirements of
the 2010/63/EU directive. Animals were housed under controlled conditions (22 °C ±
1, 40% humidity; food and water provided
ad libidum) under the supervision of a veterinarian. Cell isolation was performed from 12-14-month-old
male and female C57BL/6 subline mice. Cervical dislocation and decapitation were performed.
Removed brains were transported in transfer buffer (97% DMEM/F-12; 3% 100× penicillin/streptomycin)
(Gibco I Thermo Fisher Scientific). In a laminar hood, brains were transferred to
a Petri dish with 6 ml of tissue digestion solution (2 mg/ml collagenase A; 28 U/ml
DNase I; 0.5% 1M HEPES; 5% of heat inactivated FBS and HBSS (without Ca
2+ and Mg
2+)) (Gibco I Thermo Fisher Scientific) and minced with a scalpel. Minced tissues were
collected and incubated in an incubator for 15 min 37 °C with gentle agitation every
5 minutes. After incubation, the sample was pipetted with Pasteur pipettes of different
diameters (L/M/S) until resistance was no longer felt. The sample was incubated for
15 min 37 °C with gentle agitation every 5 minutes. The sample was filtered through
a 70 µm pore size filter. The following steps were performed on ice. The cell sample
was supplemented with HBSS (with Ca
2+ and Mg
2+) at a volume of 14 ml, centrifuged for 10 min 300 g at 4 °C at maximum acceleration
and brake. The supernatant was discarded, the sediment was slowly suspended in 2 ml
of 4 °C PBS and 1200 µL of Debris removal solution (Miltenyi Biotec). Then 4 °C PBS
was added to the sample very slowly to 14 ml. Centrifuged for 10 min 3000 g at 4 °C
at maximum acceleration and maximum brake. After centrifugation, the upper layer of
PBS and the middle layer of myelin were removed. The sample was supplemented with
PBS to a volume of 14 ml, centrifuged for 10 min 1000 g at 4 °C at maximum acceleration
and maximum brake. After removing the supernatant, the cells were suspended in 5 ml
of microglial culture medium (89% DMEM/F-12; 10% heat-inactivated FBS; 1% 100× penicillin/streptomycin)
and transferred to a 12-well plate for cultivation. After 2-4 hours, the medium from
the cells was changed to fresh microglial culture medium with 10 ng/ml M-CSF and GM-CSF
(Sigma-Aldrich). Cells were grown at 37 °C in a 5% CO
2 atmosphere. The purity of the isolated microglia culture was confirmed microscopically
using anti-Iba1 antibodies (Fig. 1). More than 90 % of culture were Iba1-positive
cells.
[0021] Microglia senescence was evaluated by Senescence Cells Histochemical Staining Kit
(Merck) which is based on the β-galactosidase activity at pH 6. Lysosomal β-galactosidase
cleaves β-D-galactose residues into β-D-galactosides. Detectable β-galactosidase activity
is the most commonly used marker of ageing or senescent cells, whether in culture
or in mammalian tissue. Specifically, the enzyme β-galactosidase hydrolyses 5-bromo-4-chloro-3-indoyl-β-d-galactopyranoside,
a colorless, soluble compound consisting of galactose bound to an indole. This reaction
releases a deep blue, insoluble product on the cell culture or in the tissue (de Mera-Rodríguez
et al., 2021) (in Figure 2, the reaction product can be seen as a dark grey dots in
the senescent cells). β-galactosidase activity is detectable in senescent cells, but
not in quiescent, immortal, or tumor cells.
[0022] Phagocytic activity was evaluated microscopically by uptake of the 1 µM size carboxylate-modified
polystyrene latex beads, fluorescent yellow-green (Merck) (Fig. 5).
Immortalization of microglial cells
[0023] In order to immortalize microglial cells, first specific PacI restriction endonuclease
cleavage sites at the 5' and 3' ends of the MAT2A gene were introduced into the commercial
pCW57.1-MAT2A plasmid (Addgene). Since the 4545 bp theoretical product of plasmid
hydrolysis after introducing a mutation at the 3' end of the MAT2A gene was visually
shorter than the 4545 bp length, the mutated part of the plasmid with PacI restriction
endonuclease hydrolysis regions were cloned back into commercial pCW57.1 -MAT2A plasmid.
After analytical hydrolysis of plasmids using Xhol, Kpnl, and PacI restriction endonucleases,
it was shown that plasmids have their expected integrity according to the hydrolysis
pattern. Gel electrophoresis results were compared to hydrolysis patterns obtained
in silico, and band sizes corresponded with theoretical sizes... After amplification
of SV40 large T antigen, cMYC, hTERT genes from plasmids, they were ligated into the
pCW57.1 mutated plasmid. After selecting the positive clones and confirming the integrity
of the plasmids, the plasmids were further used in the immortalization of microglia.
After the plasmids were constructed, the plasmids were aimed to be introduced into
microglial cells of aged mice using lentiviral transduction. The transduction of pCW57.1-c-Myc
and pCW57.1-hTERT did not induce microglial proliferation. In contrast, pCW57.1-SV40
showed to be efficient for microglia immortalization, the procedure of transduction
is described below.
[0024] Lentivirus packaging HEK293T (Thermo Fisher Scientific) cells were seeded in a 6-well
plate at a density of 2 × 10
4 cells/well in culture medium (89% DMEM; 10% FBS; 1% 100 × penicillin/streptomycin).
After 24 hours incubation cells were transfected with plasmid vectors: pCW57.1-SV40:pCMV-dR8.2
dvpr:pCMV-VSV-G (Addgene) in a 1:1:0.2 ratio (2500 ng per well ) using Lipofectamine
3000 reagent, according to the manufacturer's recommendations. The transfection mixture
was dropped onto HEK 293T cells and incubated for 6 hours. The medium was changed
to fresh culture medium and incubated for 48 hours. Microglial cells for transduction
were seeded into a well of a 6-well plate separately for each animal for microglial
cells from aged mice; neonatal microglial cells were plated at a density of 10 × 10
4 cells/well. Plates were incubated for 24 hours. The lentiviral medium generated after
transfection of HEK 293T cells was collected and filtered through a sterile 0.45 µm
pore filter, diluted 1:1 with culture medium, and then transferred onto target cells.
To improve transduction efficiency, 8 µg/ml polybrene (Merck) was added to the medium.
The cells were placed in an incubator. After 24 hours the lentivirus medium was replaced
with fresh culture medium. Cell morphology was analyzed using light microscope (Fig.
3).
Knockout of endocannabinoid receptor gene in microglial cells
[0025] Cas9(D10A) nickase is encoded in the DNA sequence of AIO-puro plasmid, which forms
a single-stranded DNA break in the complementary sequence of the DNA strand of the
gRNA, so in the case of this system, two gRNAs are used. Using the open access platform
Benchling
©, 3 gRNA pairs were selected according to the following criteria: 1. The PAM regions
are upstream of the primary gRNA and downstream of the secondary gRNA, reading from
the 5' end; 2. The lower the probability of non-target interaction and the higher
the probability of targeted interaction; 3. Location of single-strand breaks as close
as possible to the beginning of the protein coding sequence. Since the results obtained
in silico do not always correspond to the results of
in vitro studies, in order to test the gRNA and subsequently knockout the
Cnr1 gene in immortalized mouse microglial cells, AIO-puro plasmids containing 3 different
gRNA pairs for both genes were constructed. After inserting the first of the two gRNAs,
colony PCR and DNA electrophoresis were performed. Four colonies of competent
E.Coli DH5α strain bacteria transformed with constructed plasmids were tested. After correct
ligation, a 274 bp PCR fragment were visible in the gel. Plasmids were isolated from
overnight cultures of these clones and inserted with the corresponding second gRNA.
After correct ligation, PCR fragments of 274 and 744 bp were visible in the gel.
[0026] Construction of pCAG-EGxxFP-Cnr1 plasmid was performed in order to confirm that gRNA
binds to the target sequences and generates two single-stranded breaks there. Mouse
Cnr1 (524 bp long) gene fragments were amplified from tail biopsy by PCR method, purified,
restricted, purified again after restriction and ligated into pCAG-EGxxFP plasmid.
Universal Control Primer Mix of the Phire Tissue Direct PCR Kit (Thermo Fisher Scientific),
which is complementary to a fragment of the conservative non-coding region upstream
of the SOX21 gene in the mammalian genome, was also used to amplify the 237 bp PCR
product. Competent
E.Coli DH5α strain bacteria were ligatetransformed and restriction analysis was performed
to select suitable clones. After correct ligation, pCAG-EGxxFP-Cnr1 is restricted
to 3695 bp, 1972 bp and 1208 bp long fragments, which should be visible in the gel.
[0027] After the plasmids were constructed, gRNA efficiency was further tested in HEK297T
cells. After cotransfecting cells with AIO-Puro-Cnr1-gRNA and pCAG-EGxxFP-Cnr1, Cas9(D10A)
nickase should form two single-strand breaks in pCAG-EGxxFP-Cnr1 plasmid between the
EGFP coding sequence, where the target
Cnr1 gene fragment is inserted and its removal should lead to the synthesis of functional
enhanced green fluorescent protein (EGFP).
[0028] Cells were transfected with the AIO-puro-gRNA plasmid using LipfectamineTM 3000 Transfection
Reagent (Thermo Fischer Scientific) according to the manufacturer's instructions.
Two days after transfection, selection was performed with puromycin. Cells were grown
to confluence and then lysed for protein electrophoresis and Western blot to verify
that knock-out was successful.
[0029] An analogous strategy was developed and successfully applied for the
Cnr2 gene.
Table of gRNA sequences used in knockout experiments:
mCNR1-sgRNA1-1 |
ACCGGCCCACGTAGAGGAGGTCTG |
AAACCAGACCTCCTCTACGTGGGC |
mCNR1-sgRNA1-2 |
ACCGATTCAGTACGAAGATATCAA |
AAACTTGATATCTTCGTACTGAAT |
mCnr1-sgRNA2-1 |
ACCGAAGTTAGAGGGAATTTCTGT |
AAACACAGAAATTCCCTCTAACTT |
mCnr1-sgRNA2-2 |
ACCGTCCCTTCCAAGAAAAGATGA |
AAACTCATCTTTTCTTGGAAGGGAC |
mCnr1-sgRNA3-1 |
ACCGTTGGAAGGGACTACCCCTGA |
AAACTCAGGGGTAGTCCCTTCCAA |
mCnr1-sgRNA3-2 |
ACCGGGCAGGAGACAACTCCCCGT |
AAACACGGGGAGTTGTCTCCTGCC |
mCnr2-sgRNA1-1 |
ACCGGGATCATGTACTCCTTCATG |
AAACCATGAAGGAGTACATGATCC |
References
[0030] Alberts, B., Johnson, A., Lewis, J., Raff, M., Roberts, K., Walter. P. Molecular Biology
of the Cell. 4th edition. New York: Garland Science; 2002. ISBN-10: 0-8153-3218-1ISBN-10:
0-8153-4072-9 Cserép, C., Pósfai, B., Lénárt, N., Fekete, R., László, Z.I., Lele, Z., Orsolits,
B., Molnár, G., Heindl, S., Schwarcz, A.D., Ujvári, K., Környei, Z., Tóth, K., Szabadits,
E., Sperlágh, B., Baranyi, M., Csiba, L., Hortobágyi, T., Maglóczky, Z., Martinecz,
B., Szabó, G., Erd6lyi, F., Szipőcs, R., Tamkun, M.M., Gesierich, B., Duering, M.,
Katona, I., Liesz, A., Tamás, G., Dénes, A., Microglia monitor and protect neuronal
function through specialized somatic purinergic junctions. Science 2020, 367, 528-537.
[0031] De Meij, J., Alfanek, Z., Morel, L., Decoeur, F., Leyrolle, Q., Picard, K., Carrier,
M., Aubert, A., Séré, A., Lucas, C., Laforest, G., Helbling, J-Ch., Tremblay, M-E.,
Cota, D., Moisan, M-P., Marsicano, G., Layé, S., Nadjar, A. Microglial Cannabinoid
Type 1 Receptor Regulates Brain Inflammation in a Sex-Specific Manner. Cannabis Cannabinoid
Res 2021, 6(6):488-507. doi: 10.1089/can.2020.0170.
[0032] de Mera-Rodríguez, J. A., Álvarez-Hernán, G., Gañán, Y., Martín-Partido, G., Rodríguez-León,
J., Francisco-Morcillo, J. Is Senescence-Associated β-Galactosidase a Reliable in
vivo Marker of Cellular Senescence During Embryonic Development? Front. Cell Dev.
Biol., 2021, Sec. Cell Death and Survival, 9 - 2021. doi.org/10.3389/fcell.2021.623175
[0033] Lee, J.-W., Lee, I.-H., limura, T., Kong, S.W., 2021. Two macrophages, osteoclasts
and microglia: from development to pleiotropy. Bone Res 9, 11.
1. A method for generation of immortalized microglial endocannabinoid receptor gene knockout
cells, comprising the steps:
a) obtaining primary microglial cells;
b) Immortalizing the microglial cells, and
c) Producing endocannabinoid receptor gene knockout in the cells.
2. The method according to claim 1, wherein the microglial cells are mammalian microglial
cells.
3. The method according to claim 2, wherein the microglial cells are rodent microglial
cells.
4. The method according to claim 3, wherein the microglial cells are mouse microglial
cells.
5. The method according to any one of claims 1 to 4, wherein the primary microglial cells
are immortalized through viral-mediated induction of the large T-antigen.
6. The method according to claim 5, wherein the viral-mediated induction of the large
T-antigen is made by using SV40 large T antigen.
7. The method according to any one of claims 1 to 6, wherein the endocannabinoid receptor
gene knockout is produced using CRISPR-Cas system.
8. The method according to claim 7, wherein the CRISPR-Cas system is CRISPR-Cas9 nickase
system.
9. The method according to any one of claims 1 to 8, wherein the endocannabinoid receptor
gene is Cnr1 or Cnr2.
10. An immortalized microglial endocannabinoid receptor gene knockout cell obtained by
the method according to any one of the claims from 1 to 9.
11. The immortalized microglial endocannabinoid receptor gene knockout cell according
to claim 10, wherein the endocannabinoid receptor gene is Cnr1.
12. The immortalized microglial endocannabinoid receptor gene knockout cell according
to claim 10, wherein the endocannabinoid receptor gene is Cnr2.